MAPK4 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid cell line, designed for loss-of-function analysis of the atypical mitogen-activated protein kinase MAPK4 (ERK4). This heterogeneous pool of gene-edited cells harbors targeted disruptions of the MAPK4 locus, offering a robust model to assess MAPK4-dependent cellular functions without the biases of clonal selection.
The Raji cell line originates from a human Burkitt lymphoma, an Epstein-Barr virus (EBV)-positive B lymphocyte model that recapitulates key aspects of humoral immunity, including antibody production and antigen presentation. Its rapid proliferation and well-characterized signaling networks render it an indispensable tool for dissecting B-cell biology and lymphomagenesis.
MAPK4, an atypical MAP kinase, operates within the broader MAPK signaling pathway and is activated downstream of growth factors, EGFR ligands, MEK kinases, Ras signaling, and oxidative stress. Upon activation, MAPK4 phosphorylates substrates such as MAPKAPK5 and modulates the activity of transcription factors including c-Fos, c-Jun, ATF2, and p53, thereby orchestrating cell proliferation, differentiation, and migration. It engages in interactions with importin-??, scaffold proteins, and the related kinase ERK3, integrating signals from the Ras-Raf-MEK-ERK cascade and stress-activated kinase pathways to fine-tune gene expression and cell fate decisions.
In the context of Raji B lymphocytes, disruption of MAPK4 is particularly significant for unraveling the molecular mechanisms underlying B-cell malignancies, Burkitt lymphoma, and autoimmune disorders. Loss of MAPK4 function enables researchers to probe altered proliferative and apoptotic responses, changes in antigen presentation, and perturbations in cytokine signaling, thereby illuminating pathways that drive lymphomagenesis and revealing potential therapeutic vulnerabilities.
This polyclonal knockout cell pool is ideally suited for functional studies of MAP kinase signaling in B-cell lymphoma, cancer cell biology, drug target validation, and analyses of lymphocyte activation and apoptosis. Experimental approaches include Western blotting to measure MAPKAPK5 phosphorylation, RT-qPCR for downstream gene expression profiling, flow cytometry for immunophenotyping, co-immunoprecipitation to assess MAPK4 interactions, immunofluorescence for subcellular localization, and apoptosis assays. For additional information, please contact Ascent Research.
